Physician profile
Benjamin Herms
NPI 1730218876
$954.19
in general payments reported to CMS, 2019-2025
18 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.80 · 2020: $148 · 2021: $36.42 · 2023: $166 · 2024: $233 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.72 |
| Education | $116.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $132.99 | 2020-2025 | Opdivo |
| Abbvie INC. | $130.45 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $127.41 | 2023-2025 | |
| Astellas Pharma US INC | $111.49 | 2020-2024 | Vyloy |
| Janssen Biotech, INC. | $99.99 | 2025 | Erleada |
| Pfizer INC. | $84.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.42 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $45.31 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $41.90 | 2023-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $29.55 | 2023 | Imbruvica |
| Genentech USA, INC. | $23.00 | 2024 | Tecentriq, Alecensa |
| Sun Pharmaceutical Industries INC. | $22.91 | 2024 | |
| Eisai INC. | $19.00 | 2023 | |
| Glaxosmithkline, LLC. | $16.76 | 2025 | Jemperli, Zejula |
| Gilead Sciences, INC. | $11.92 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $11.50 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Herms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.